A detailed history of China Universal Asset Management Co., Ltd. transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 17,024 shares of CRBU stock, worth $27,238. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,024
Previous 17,024 -0.0%
Holding current value
$27,238
Previous $88,000 1.14%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$4.82 - $8.26 $32,766 - $56,151
6,798 Added 66.48%
17,024 $88,000
Q4 2023

May 21, 2024

SELL
$3.58 - $6.25 $24,336 - $42,487
-6,798 Reduced 39.93%
10,226 $58,000
Q4 2023

Jan 23, 2024

BUY
$3.58 - $6.25 $28,525 - $49,800
7,968 Added 352.88%
10,226 $59,000
Q3 2023

May 21, 2024

BUY
$4.08 - $8.14 $5,928 - $11,827
1,453 Added 180.5%
2,258 $10,000
Q3 2023

Oct 30, 2023

BUY
$4.08 - $8.14 $5,928 - $11,827
1,453 Added 180.5%
2,258 $11,000
Q2 2023

May 21, 2024

SELL
$4.04 - $5.47 $88 - $120
-22 Reduced 2.66%
805 $3,000
Q2 2023

Jul 27, 2023

SELL
$4.04 - $5.47 $88 - $120
-22 Reduced 2.66%
805 $3,000
Q1 2023

May 21, 2024

BUY
$4.3 - $7.78 $890 - $1,610
207 Added 33.39%
827 $4,000
Q1 2023

Apr 27, 2023

BUY
$4.3 - $7.78 $890 - $1,610
207 Added 33.39%
827 $4,000
Q4 2022

May 21, 2024

SELL
$5.57 - $11.01 $91,370 - $180,608
-16,404 Reduced 96.36%
620 $3,000
Q4 2022

Jan 31, 2023

BUY
$5.57 - $11.01 $278 - $550
50 Added 8.77%
620 $4,000
Q3 2022

Oct 21, 2022

BUY
$5.34 - $12.79 $3,043 - $7,290
570 New
570 $6,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $97.3M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.